Venus Remedies has received its second incentive payout under the Government of India’s Production Linked Incentive (PLI) Scheme for Pharmaceuticals, accounting for 75 percent of the total incentive eligible for FY 2024–25—a clear endorsement of the company’s execution and scale-up momentum.

The latest disbursement follows Venus Remedies’ successful achievement of the PLI scheme’s prescribed investment, production and sales milestones. Back-to-back payouts underscore the company’s ability to meet the programme’s stringent benchmarks, reinforcing its track record of disciplined execution and sustained performance.

A global leader in fixed-dosage injectable manufacturing and among the select companies approved under PLI 2.0, Venus Remedies is set to deploy the incentives to expand manufacturing capacity, integrate advanced technologies and deepen its role in India’s fast-evolving pharmaceutical ecosystem. The support aligns with the company’s long-term strategy focused on innovation-led growth, domestic manufacturing strength and job creation.

Commenting on the development, Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, said: “The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities."

"These incentives will support capacity expansion, enable investments in advanced and globally competitive technologies, and deepen our contribution to a resilient and self-reliant healthcare ecosystem. As we scale responsibly, we remain aligned with national healthcare and industrial priorities, with a strong focus on quality, supply-chain security, and long-term value creation.”

Launched under the Atmanirbhar Bharat initiative, the Government of India’s PLI scheme is designed to accelerate domestic investment, boost incremental production and enhance global competitiveness across strategic manufacturing sectors, including pharmaceuticals. Backed by an outlay of ₹15,000 crore from FY 2020–21 to FY 2028–29, the scheme has emerged as a cornerstone of India’s pharmaceutical manufacturing resurgence.

The impact is already visible. India has shifted from a net bulk drug import deficit of ₹1,930 crore in FY 2021–22 to a net exporter position with a ₹2,280 crore surplus in FY 2024–25.

In its first three years, pharma sales under the PLI scheme surpassed ₹2.66 lakh crore, including exports worth ₹1.70 lakh crore, with domestic value addition reaching 83.70 percent as of March 2025—marking a decisive step toward supply-chain resilience and reduced import dependence.